Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DBU13L
|
|||
| Drug Name |
Cavrotolimod
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1 | [1] | |
| Company |
Exicure
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03684785) Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Exicure. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.